Dynavax Technologies Corporation
DVAXDrugs in Pipeline
8
Phase 3 Programs
4
Upcoming Catalysts
1
Next Catalyst
May 29, 2026
5dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
rF1V-1018 Phase 2 Results Expected
Primary completion for rF1V-1018 trial (NCT07207408) in Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis
SourceHEPLISAV-B
Chronic Kidney Disease
HEPLISAV
Hepatitis B
Engerix-B
Hepatitis B
Fendrix
End Stage Renal Disease
Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate
Rhinitis, Allergic, Seasonal
Z-1018
Shingles
rF1V-1018
Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis
rF1V vaccine
Plague, Pneumonic
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
HEPLISAV-B | Phase 3 | Chronic Kidney Disease | - | - |
HEPLISAV | Phase 3 | Hepatitis B | - | - |
Engerix-B | Phase 3 | Hepatitis B | - | - |
Fendrix | Phase 3 | End Stage Renal Disease | - | - |
Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate | Phase 2 | Rhinitis, Allergic, Seasonal | - | - |
Z-1018 | Phase 2 | Shingles | - | - |
rF1V-1018 | Phase 2 | Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis | - | - |
rF1V vaccine | Phase 2 | Plague, Pneumonic | - | - |
Hepatitis B
2 drugs in this indication
Rhinitis, Allergic, Seasonal
1 drug in this indication
Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis
1 drug in this indication
Plague, Pneumonic
1 drug in this indication
End Stage Renal Disease
1 drug in this indication
Shingles
1 drug in this indication
Chronic Kidney Disease
1 drug in this indication
Healthy
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)